Gelesis Holdings Inc.
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Furt… Read more
Market Cap & Net Worth: Gelesis Holdings Inc. (GLSHQ)
Gelesis Holdings Inc. (PINK:GLSHQ) has a market capitalization of $0.91 ($0.91) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #45822 globally and #14359 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gelesis Holdings Inc.'s stock price $0.00 by its total outstanding shares 9069 (9.07K).
Gelesis Holdings Inc. Market Cap History: 2023 to 2025
Gelesis Holdings Inc.'s market capitalization history from 2023 to 2025. Data shows growth from $18.14 to $0.91 (0.00% CAGR).
Gelesis Holdings Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gelesis Holdings Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GLSHQ by Market Capitalization
Companies near Gelesis Holdings Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Gelesis Holdings Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Gelesis Holdings Inc. Historical Marketcap From 2023 to 2025
Between 2023 and today, Gelesis Holdings Inc.'s market cap moved from $18.14 to $ 0.91, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $0.91 | -95.24% |
| 2024 | $19.04 | +5.00% |
| 2023 | $18.14 | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Gelesis Holdings Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $0.91 USD |
| MoneyControl | $0.91 USD |
| MarketWatch | $0.91 USD |
| marketcap.company | $0.91 USD |
| Reuters | $0.91 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.